

Tissue Regeneration Therapeutics Inc. (TRT) raises \$3.25 Million to accelerate the development of its Mesenchymal Cell therapeutics platform

Toronto, Canada, July 10th 2013: Tissue Regeneration Therapeutics Inc. (TRT) today announced it has entered into a structured royalty sale transaction with SWK Holdings of Dallas, Texas. The transaction, valued at US\$3.25 million, was based on the strength of two TRT technology licenses in the family cord banking services sector. Toronto-based Sapien Capital Partners, acted as strategic and financial advisor to TRT.

TRT is a progressive biotechnology company with a focus on the commercial development of our patented **Human Umbilical Cord PeriVascular Cell (HUCPVC)** platform technology. TRT has discovered the world's richest source of mesenchymal stromal cells (MSCs) with potent regenerative, angiogenic, anti-inflammatory, immuno-regulatory and anti-bacterial properties. Unique advantages of the TRT platform HUCPVC technology are founded on the highly enriched source of these important cells compared to other tissue sources. Specifically, HUCPVCs represent high cell yields at harvest from tissue normally discarded at birth; high frequencies of mesenchymal stromal cells within the harvested population, their increased biological potential compared to cells derived from adult tissues and their inexhaustible supply.

About TRT

TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the commercial development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology. TRT is the first company in the world to have issued and allowed patents in the USA, Europe and Australasia, for extraction of these unique cells from umbilical cord tissue. TRT provides license opportunities to collaborating partner companies in the family banking, regenerative medicine and defense sectors. Additional information is available at <http://www.verypowerfulbiology.com>.

About SWK

SWK is a specialized finance company with a focus on the global healthcare sector. SWK partners with ethical product marketers and royalty holders to provide flexible financing solutions at an attractive cost of capital to create long-term value for both SWK's business partners and its investors. SWK believes its financing structures achieve an optimal partnership for companies, institutions and inventors seeking capital for expansion or capital and estate planning by allowing its partners to monetize future cash flow with minimal dilution to their equity stakes. Additional information on the life science finance market is available on the Company's website at www.swkhold.com.

